Categories
Article Biodistribution In-vivo Studies Mixed Therapies (BNCT + Other Therapies) Radiobiology Year 2004

Combination of boron neutron capture therapy and external beam radiotherapy for brain tumors

International Journal of Radiation Oncology Biology Physics, 2004

Authors:   Rolf Barth,John Grecula,Weilan Yang,Joan Rotaru,Marta Nawrocky,Nilendu Gupta,Brent Albertson,Amy Ferketich,Melvin Moeschberger,Jeffrey Coderre,Einar Rofstad
Journal: International Journal of Radiation Oncology Biology Physics
https://doi.org/10.1016/S0360-3016(03)01613-4
Abstract: Purpose: Boron neutron capture therapy (BNCT) has been used clinically as a single modality treatment for high-grade gliomas and melanomas metastatic to the brain. The purpose of the present study was to determine whether its efficacy could be enhanced by an X-ray boost administered after BNCT. Two brain tumor models were used, the F98 glioma as a model for primary brain tumors and the MRA 27 human melanoma as a model for metastatic brain tumors. Methods and Materials: For biodistribution studies, either 105 F98 glioma cells were implanted stereotactically into the brains of syngeneic Fischer rats or 106 MRA 27 melanoma cells were implanted intracerebrally into National Institutes of Health (NIH)-rnu nude rats. Biodistribution studies were performed 11-13 days after implantation of the F98 glioma and 20-24 days after implantation of the MRA 27 melanoma. Animals bearing the F98 glioma received a combination of two boron-containing drugs, sodium borocaptate at a dose of 30 mg/kg and boron phenylalanine (BPA) at a dose of 250 mg/kg. MRA 27 melanoma-bearing rats received BPA (500 mg/kg) containing an equivalent amount of 10B (27 mg B/kg). The drugs were administered by either intracarotid or i.v. injection. Results: The tumor boron concentration after intracarotid injection was $sim$50% greater in the F98 glioma and MRA 27 melanoma after intracarotid injection (20.8 and 36.8 $mu$g/g, respectively) compared with i.v. injection (11.2 and 19.5 $mu$g/g, respectively). BNCT was carried out at the Brookhaven National Laboratory Medical Research Reactor $sim$14 days after tumor implantation of either the F98 glioma or the MRA 27 melanoma. Approximately 7-10 days after BNCT, subsets of animals were irradiated with 6-MV photons, produced by a linear accelerator at a total dose of 15 Gy, delivered in 5-Gy daily fractions. F98 glioma-bearing rats that received intracarotid or i.v. sodium borocaptate plus BPA, followed 2.5 h later by BNCT and 7-10 days later by X-rays, had similar mean survival times (61 days and 53 days, respectively, p = 0.25), and the non X-irradiated, BNCT-treated animals had a mean survival time of 52 and 40 days, respectively, for intracarotid vs. i.v. injection; the latter was equivalent to that of the irradiated animals. The corresponding survival time for MRA 27 melanoma-bearing rats that received intracarotid or i.v. BPA, followed by BNCT and then X-irradiation, was 75 and 82 days, respectively (p = 0.5), 54 days without X-irradiation (p = 0.0002), 37 days for X-irradiation alone, and 24 days for untreated controls. In contrast to the data obtained with the F98 glioma, MRA 27 melanoma-bearing rats that received i.v. BPA, followed by BNCT, had a highly significant difference in mean survival time compared with the irradiated controls (54 vs. 37 days, p = 0.008). Conclusion: Our data are the first to suggest that a significant therapeutic gain may be obtained when BNCT is combined with an X-ray boost. Additional experimental studies are required to determine the optimal combination of X-radiation and neutron doses and whether it is more advantageous to administer the photon boost before or after BNCT. {textcopyright} 2004 Elsevier Inc.